These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 7917773)

  • 21. Pharmacodynamics and pharmacokinetics of two dose regimens of befloxatone, a new reversible and selective monoamine oxidase inhibitor, at steady state in healthy volunteers.
    Patat A; le Coz F; Dubruc C; Gandon JM; Durrieu G; Cimarosti I; Jezequel S; Curet O; Zieleniuk I; Allain H; Rosenzweig P
    J Clin Pharmacol; 1996 Mar; 36(3):216-29. PubMed ID: 8690815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of depression, cigarette smoking, and age on monoamine oxidase B in amygdaloid nuclei.
    Karolewicz B; Klimek V; Zhu H; Szebeni K; Nail E; Stockmeier CA; Johnson L; Ordway GA
    Brain Res; 2005 May; 1043(1-2):57-64. PubMed ID: 15862518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
    Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG
    Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of monoamine oxidase A and B activities by imidazol(ine)/guanidine drugs, nature of the interaction and distinction from I2-imidazoline receptors in rat liver.
    Ozaita A; Olmos G; Boronat MA; Lizcano JM; Unzeta M; García-Sevilla JA
    Br J Pharmacol; 1997 Jul; 121(5):901-12. PubMed ID: 9222546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of MAO-B occupancy in the brain with PET and [11C]-L-deprenyl-D2: a dose-finding study with a novel MAO-B inhibitor, EVT 301.
    Hirvonen J; Kailajärvi M; Haltia T; Koskimies S; Någren K; Virsu P; Oikonen V; Sipilä H; Ruokoniemi P; Virtanen K; Scheinin M; Rinne JO
    Clin Pharmacol Ther; 2009 May; 85(5):506-12. PubMed ID: 19129751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease.
    Palfreyman MG; McDonald IA; Zreika M; Cremer G; Haegele KD; Bey P
    J Neural Transm Suppl; 1993; 40():101-11. PubMed ID: 8294896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. Parkinson Study Group.
    Ann Neurol; 1993 Apr; 33(4):350-6. PubMed ID: 8489205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human recombinant monoamine oxidase B as reliable and efficient enzyme source for inhibitor screening.
    Novaroli L; Reist M; Favre E; Carotti A; Catto M; Carrupt PA
    Bioorg Med Chem; 2005 Nov; 13(22):6212-7. PubMed ID: 16054369
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The properties of B-form monoamine oxidase in mitochondria from monkey platelet.
    Obata T; Aomine M
    Res Commun Mol Pathol Pharmacol; 2009-2010; 122-123(1-6):13-26. PubMed ID: 22032088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MAO inhibitors, clorgyline and lazabemide, prevent hydroxyl radical generation caused by brain ischemia/reperfusion in mice.
    Suzuki T; Akaike N; Ueno K; Tanaka Y; Himori N
    Pharmacology; 1995 Jun; 50(6):357-62. PubMed ID: 7568334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and pharmacodynamics of the monoamine oxidase B inhibitor mofegiline assessed during a phase I dose tolerance trial.
    Stoltz M; Reynolds D; Elkins L; Salazar D; Weir S
    Clin Pharmacol Ther; 1995 Sep; 58(3):342-53. PubMed ID: 7554709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ro 19-6327, a reversible and highly selective monoamine, oxidase B inhibitor: a novel tool to explore the MAO-B function in humans.
    Haefely WE; Kettler R; Keller HH; Da Prada M
    Adv Neurol; 1990; 53():505-12. PubMed ID: 2122653
    [No Abstract]   [Full Text] [Related]  

  • 34. Locomotor effects of imidazoline I2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway.
    Macinnes N; Duty S
    Br J Pharmacol; 2004 Dec; 143(8):952-9. PubMed ID: 15545290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety study of lazabemide (Ro19-6327), a new MAO-B inhibitor, on cardiac arrhythmias and blood pressure of patients with Parkinson's disease.
    Narabayashi H; Yamaguchi T; Sugi K; Mitamura H; Mizuno Y; Nakashima M
    Clin Neuropharmacol; 1999; 22(6):340-6. PubMed ID: 10626094
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron emission tomography measurement of brain MAO-B inhibition in patients with Alzheimer's disease and elderly controls after oral administration of sembragiline.
    Sturm S; Forsberg A; Nave S; Stenkrona P; Seneca N; Varrone A; Comley RA; Fazio P; Jamois C; Nakao R; Ejduk Z; Al-Tawil N; Akenine U; Halldin C; Andreasen N; Ricci B
    Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):382-391. PubMed ID: 27633250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The synthesis and evaluation of sesamol and benzodioxane derivatives as inhibitors of monoamine oxidase.
    Engelbrecht I; Petzer JP; Petzer A
    Bioorg Med Chem Lett; 2015 May; 25(9):1896-900. PubMed ID: 25857942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The properties of B-form monoamine oxidase in mitochondria from monkey platelet.
    Obata T; Aomine M
    Res Commun Mol Pathol Pharmacol; 2009-2010; 122-123():13-26. PubMed ID: 25022028
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
    Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
    J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.